Inhalation API manufacturer Inke has announced a €9 million expansion of its manufacturing facility in Castellbisbal, Barcelona, Spain "to reinforce focus on inhalation micronized APIs," with the aim of tripling its production capacity by 2024. According to Inke, the site currently makes 34 APIs for pharma companies in the US, Europe, Turkey, Japan, China, and Korea, … [Read more...] about Inke to triple inhalation API manufacturing capacity
News
Rensselaer and Albany Medical College get funding for development of pentosan polysulfate nasal spray against COVID-19
Researchers from Rensselaer Polytechnic Institute (RPI) and Albany Medical College will use a $500,000 grant from the New York State Biodefense Commercialization Fund for early development of a pentosan polysulfate (PPS) nasal spray for the prevention of respiratory infections, including COVID-19. PPS is currently approved in the US as an oral treatment for bladder … [Read more...] about Rensselaer and Albany Medical College get funding for development of pentosan polysulfate nasal spray against COVID-19
Positive Phase 1 results for TFF Pharmaceuticals’ dry powder niclosamide
TFF Pharmaceuticals announced that a Phase 1 SAD/MAD study of its dry powder niclosamide found that inhalation of the formulation was well tolerated at all doses evaluated and that data from the study suggest moving into a Phase 2 study with a twice daily 6 mg dose. The company, which recently said that the dry powder niclosamide completely inhibited the Omicron … [Read more...] about Positive Phase 1 results for TFF Pharmaceuticals’ dry powder niclosamide
SK Bioscience partners with IAVI and University of Washington on development of binder protein nasal spray against COVID-19
SK Bioscience announced that it has partnered with nonprofit research organization IAVI on development of an antiviral nasal spray based on a protein developed by David Baker at the University of Washington. The company noted that it will get $2.2 million out of a grant by the Bill & Melinda Gates Foundation to IAVI for the project. The Gates Foundation also … [Read more...] about SK Bioscience partners with IAVI and University of Washington on development of binder protein nasal spray against COVID-19
Intranasal minibinder proteins effective against SARS-CoV-2 in preclinical studies
Researchers from Northwestern University, the University of Washington, and Washington University at St. Louis have published data demonstrating that select miniproteins neutralized SARS-CoV-2 better than mAbs currently in use for the treatment of COVID-19. The multivalent minibinder demonstrated potent activity against all variants of the virus tested, including … [Read more...] about Intranasal minibinder proteins effective against SARS-CoV-2 in preclinical studies
Receptor Life Sciences raises $9.7 million for development of RLS103 dry powder CBD
Receptor Life Sciences said that it has closed a $9.7 million Series A-1 financing and will use the proceeds for clinical development of its RLS103 cannabidiol DPI. RLS103 is based on MannKind Corporation's Technosphere particle engineering technology, which Receptor licensed for use with its cannabinoid products in 2016. The company is developing the inhaled CBD … [Read more...] about Receptor Life Sciences raises $9.7 million for development of RLS103 dry powder CBD
Upperton Pharma Solutions launches nasal delivery development platform
UK-based CDMO Upperton Pharma Solutions has launched a nasal delivery development platform called UpperNose, the company said. The UpperNose services include pre-formulation analyses, dosage form selection, and formulation and process development through to clinical trial manufacturing. Upperton Chief Scientific Officer Richard Johnson said, "The delivery of … [Read more...] about Upperton Pharma Solutions launches nasal delivery development platform
Gates Foundation provides grant for development of aerosolized surfactant for the treatment of RDS in newborns
The Lundquist Institute for Biomedical Innovation has announced that the Bill & Melinda Gates Foundation has awarded a 2-year grant of $471,858 to principal investigator Frans Walther for further development of an aerosolized synthetic lung surfactant for the treatment of respiratory distress syndrome (RDS) in newborn babies. In March 2021, the institute announced … [Read more...] about Gates Foundation provides grant for development of aerosolized surfactant for the treatment of RDS in newborns
FDA allows additional MS patients in intranasal Foralumab expanded access program
Tiziana Life Sciences said that the FDA has issued a Study May Proceed letter allowing Brigham and Women’s Hospital (BWH) to treat an additional eight patients with secondary progressive multiple sclerosis (SPMS) with Tiziana's intranasal Foralumab under an Intermediate-Size Patient Population Expanded Access IND. The agency evaluated data from treatment of two … [Read more...] about FDA allows additional MS patients in intranasal Foralumab expanded access program
Respira initiates Phase 2b trial of RT234 inhaled vardenafil for PAH
Respira Therapeutics has announced the initiation of a Phase 2b trial of its RT234 dry powder vardenafil in patients with pulmonary arterial hypertension (PAH). The open label study will include two cohorts, with the first receiving a single 0.5 mg dose of RT234 via the Axial Oscillating Sphere inhaler and the second getting a 1 mg dose (2 x 0.5 mg). United … [Read more...] about Respira initiates Phase 2b trial of RT234 inhaled vardenafil for PAH